Healthcare provider profile · identity verified

Christopher Bruce Cutter, MD

Allopathic & Osteopathic Physicians|Family Medicine · SAN MARCOS, CA · NPI 1538274287

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Christopher Bruce Cutter, MD received $107.06 in general payments during 2025 across 3 reported records.

Boston Scientific Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$107.06

3 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Boston Scientific Corporation Unresolved — no canonical attribution shown $107.06100.0%32025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$107.063

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
WATCHMAN FLX
Normalized: watchman flx
Device Boston Scientific Corporation $107.06 3 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium388117
Levothyroxine SodiumLevothyroxine Sodium24557
Losartan PotassiumLosartan Potassium19364
LisinoprilLisinopril14742
Tamsulosin HclTamsulosin Hcl13346
OmeprazoleOmeprazole13031
Amlodipine BesylateAmlodipine Besylate12347
Rosuvastatin CalciumRosuvastatin Calcium12135
Metformin Hcl ErMetformin Hcl9228
GabapentinGabapentin8021
HydrochlorothiazideHydrochlorothiazide7528
Metformin HclMetformin Hcl7023
Pantoprazole SodiumPantoprazole Sodium6826
Metoprolol SuccinateMetoprolol Succinate6522
Sertraline HclSertraline Hcl6520
FurosemideFurosemide6418
EzetimibeEzetimibe6325
SimvastatinSimvastatin6117
CarvedilolCarvedilol5613
Potassium ChloridePotassium Chloride5618
AllopurinolAllopurinol5317
Albuterol Sulfate HfaAlbuterol Sulfate4923
Pravastatin SodiumPravastatin Sodium4913
FinasterideFinasteride47suppressed
Trazodone HclTrazodone Hcl4714
TrulicityDulaglutide47suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen4311
MirtazapineMirtazapine39suppressed
AlprazolamAlprazolam3712
AtenololAtenolol36suppressed
JardianceEmpagliflozin3612
Benazepril HclBenazepril Hcl35suppressed
Metoprolol TartrateMetoprolol Tartrate35suppressed
Zolpidem TartrateZolpidem Tartrate30suppressed
Quetiapine FumarateQuetiapine Fumarate28suppressed
EliquisApixaban2711
Doxycycline MonohydrateDoxycycline Monohydrate2523
Montelukast SodiumMontelukast Sodium25suppressed
Escitalopram OxalateEscitalopram Oxalate24suppressed
FamotidineFamotidine24suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24suppressed
Duloxetine HclDuloxetine Hcl23suppressed
Terazosin HclTerazosin Hcl23suppressed
ClopidogrelClopidogrel Bisulfate22suppressed
Fluticasone PropionateFluticasone Propionate22suppressed
Hydralazine HclHydralazine Hcl22suppressed
MounjaroTirzepatide21suppressed
OzempicSemaglutide21suppressed
Azelastine HclAzelastine Hcl20suppressed
Bupropion XlBupropion Hcl20suppressed
FarxigaDapagliflozin Propanediol19suppressed
MeloxicamMeloxicam19suppressed
Solifenacin SuccinateSolifenacin Succinate19suppressed
SpironolactoneSpironolactone19suppressed
CelecoxibCelecoxib18suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18suppressed
Buspirone HclBuspirone Hcl17suppressed
Folic AcidFolic Acid17suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17suppressed
Paroxetine HclParoxetine Hcl17suppressed
Triamcinolone AcetonideTriamcinolone Acetonide1715
Felodipine ErFelodipine16suppressed
Memantine HclMemantine Hcl16suppressed
PregabalinPregabalin16suppressed
BaclofenBaclofen15suppressed
ColchicineColchicine15suppressed
Olmesartan MedoxomilOlmesartan Medoxomil15suppressed
Tramadol HclTramadol Hcl15suppressed
ValsartanValsartan15suppressed
EstradiolEstradiol14suppressed
SotalolSotalol Hcl14suppressed
FebuxostatFebuxostat13suppressed
GlimepirideGlimepiride13suppressed
JanuviaSitagliptin Phosphate13suppressed
Propranolol HclPropranolol Hcl13suppressed
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid13suppressed
Wixela InhubFluticasone Propion/Salmeterol13suppressed
AcyclovirAcyclovir12suppressed
Humalog Kwikpen U-100Insulin Lispro12suppressed
HydrocortisoneHydrocortisone12suppressed
IbuprofenIbuprofen12suppressed
Methenamine HippurateMethenamine Hippurate12suppressed
Oxycodone HclOxycodone Hcl12suppressed
PrednisonePrednisone12suppressed
Propranolol Hcl ErPropranolol Hcl12suppressed
Terbinafine HclTerbinafine Hcl12suppressed
Citalopram HbrCitalopram Hydrobromide11suppressed
LorazepamLorazepam11suppressed
Nifedipine ErNifedipine11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $107.06 · 3 records Boston Scientific Corporation WATCHMAN FLX
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error